Literature DB >> 17034579

T cell receptor excision circles (TRECs), CD4+, CD8+, and their CD45RO+, and CD45RA+, subpopulations in hepatitis C virus (HCV)-HIV-co-infected patients during treatment with interferon alpha plus ribavirin: analysis in a population on effective antiretroviral therapy.

A Arizcorreta1, M Márquez, C Fernández-Gutiérrez, E Pérez Guzmán, F Brun, M Rodríguez-Iglesias, J A Girón-González.   

Abstract

Interferon (IFN)-alpha induced CD4(+) T lymphopenia is a toxic effect of the treatment of chronic hepatitis C virus (HCV) in human immunodeficiency virus (HIV)-co-infected patients. To increase the knowledge about this secondary effect, we performed an analysis of the evolution of the T cell receptor excision circles (TRECs), CD4(+) and CD8(+) T cells and of their CD45RO(+) and CD45RA(+) subpopulations during the treatment of chronic hepatitis HCV with peginterferon alpha (pegIFN-alpha) + ribavirin. Twenty HCV/HIV-co-infected patients, with undetectable HIV load after highly active antiretroviral therapy (HAART), were treated with pegIFN-alpha + ribavirin. TRECs were determined using real-time polymerase chain reaction. CD4(+) and CD8(+) T cells and their CD45RO(+) and CD45RA(+) subpopulations were analysed by two-colour flow cytometry. Median baseline CD4(+) and CD8(+) T cells were 592 mm(3) and 874 mm(3), respectively. Median baseline CD45RO(+) subpopulation was 48% for CD4(+) T and 57% for CD8(+) T lymphocytes. A progressive decrease in both T cell populations, as well as of their CD45RO(+) and CD45RA(+) subpopulations, was detected, with a difference between the baseline and nadir levels approaching 50%. The evolution of T cell populations and TRECs was independent of the response to the treatment. T lymphocytes and their subpopulations returned to baseline levels at 24 weeks after the end of treatment, with the exception of the T CD4(+) CD45RA(+) subpopulation. The ratio of CD4(+) CD45RO(+)/CD4(+) CD45RA(+) increased from 0.89 (baseline) to 1.44 (24 weeks after the end of the therapy). TRECs/ml did not return to the basal values. In conclusion, a significant reduction of CD4(+) and CD8(+) T cells, and of their CD45RA(+) and CD45RO(+) subpopulations, in HIV/HCV co-infected patients treated with pegIFN-alpha was observed. Both subpopulations increased after the suppression of treatment, but the CD4(+) CD45RA subpopulation did not reach the basal levels as a consequence, at least in part, of a decrease in thymic production.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17034579      PMCID: PMC1942067          DOI: 10.1111/j.1365-2249.2006.03220.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  49 in total

1.  11-color, 13-parameter flow cytometry: identification of human naive T cells by phenotype, function, and T-cell receptor diversity.

Authors:  S C De Rosa; L A Herzenberg; L A Herzenberg; M Roederer
Journal:  Nat Med       Date:  2001-02       Impact factor: 53.440

Review 2.  Mechanism of action of ribavirin in the combination treatment of chronic HCV infection.

Authors:  Johnson Y N Lau; Robert C Tam; T Jake Liang; Zhi Hong
Journal:  Hepatology       Date:  2002-05       Impact factor: 17.425

Review 3.  Management of chronic viral hepatitis in HIV-infected patients: Spanish Consensus Conference. October 2000.

Authors:  Javier García-Samaniego; Vicente Soriano; José María Miró; Jorge Del Romero; Miguel Bruguera; Jesús Castilla; Juan Ignacio Esteban; Juan Gonźlez; Eduardo Lissen; Alberto Moreno; Santiago Moreno; Ricardo Moreno-Otero; Enrique Ortega; Carmen Quereda; Manuel Rodríguez; José María Sánchez-Tapias
Journal:  HIV Clin Trials       Date:  2002 Mar-Apr

4.  Efficacy and safety of pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.

Authors:  Miguel Santin; Evelyn Shaw; M Jose Garcia; Antonio Delejido; Eduardo Rodriguez de Castro; Rosa Rota; Jordi Altés; Francisco Baguena; Silvia Valero; Montserrat Sala; Aurora Casanova
Journal:  AIDS Res Hum Retroviruses       Date:  2006-04       Impact factor: 2.205

Review 5.  Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C.

Authors:  Lesley J Scott; Caroline M Perry
Journal:  Drugs       Date:  2002       Impact factor: 9.546

6.  Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.

Authors:  R S Hogg; B Yip; K J Chan; E Wood; K J Craib; M V O'Shaughnessy; J S Montaner
Journal:  JAMA       Date:  2001-11-28       Impact factor: 56.272

7.  T-cell repopulation and thymic volume in HIV-1-infected adult patients after highly active antiretroviral therapy.

Authors:  Jaime M Franco; Amalia Rubio; Manuel Martínez-Moya; Manuel Leal; Elena Merchante; Armando Sánchez-Quijano; Eduardo Lissen
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

8.  Reevaluation of T cell receptor excision circles as a measure of human recent thymic emigrants.

Authors:  Ping Ye; Denise E Kirschner
Journal:  J Immunol       Date:  2002-05-15       Impact factor: 5.422

9.  Possible mechanism of toxicity of zidovudine by induction of apoptosis of CD4+ and CD8+ T-cells in vivo.

Authors:  O Benveniste; J Estaquier; J D Lelièvre; J L Vildé; J C Ameisen; C Leport
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2001-12       Impact factor: 3.267

Review 10.  Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.

Authors:  Patrick G Yeni; Scott M Hammer; Charles C J Carpenter; David A Cooper; Margaret A Fischl; Jose M Gatell; Brian G Gazzard; Martin S Hirsch; Donna M Jacobsen; David A Katzenstein; Julio S G Montaner; Douglas D Richman; Michael S Saag; Mauro Schechter; Robert T Schooley; Melanie A Thompson; Stefano Vella; Paul A Volberding
Journal:  JAMA       Date:  2002-07-10       Impact factor: 56.272

View more
  6 in total

1.  Treatment of SIV-infected sooty mangabeys with a type-I IFN agonist results in decreased virus replication without inducing hyperimmune activation.

Authors:  Thomas H Vanderford; Chloe Slichter; Kenneth A Rogers; Benton O Lawson; Rend Obaede; James Else; Francois Villinger; Steven E Bosinger; Guido Silvestri
Journal:  Blood       Date:  2012-05-01       Impact factor: 22.113

2.  Altered phenotype and functionality of circulating immune cells characterize adult patients with nonalcoholic steatohepatitis.

Authors:  María Eugenia Inzaugarat; Nazarena Eugenia Ferreyra Solari; Luis Ariel Billordo; Raquel Abecasis; Adrian C Gadano; Alejandra Claudia Cherñavsky
Journal:  J Clin Immunol       Date:  2011-08-17       Impact factor: 8.317

3.  Could a loss of memory T cells limit responses to hepatitis C virus (HCV) antigens in blood leucocytes from patients chronically infected with HCV before and during pegylated interferon-alpha and ribavirin therapy?

Authors:  S Lee; T Hammond; M W Watson; J P Flexman; W Cheng; S Fernandez; P Price
Journal:  Clin Exp Immunol       Date:  2010-04-09       Impact factor: 4.330

4.  Altered thymic function during interferon therapy in HCV-infected patients.

Authors:  Stephanie Beq; Sandra Rozlan; Sandy Pelletier; Bernard Willems; Julie Bruneau; Jean-Daniel Lelievre; Yves Levy; Naglaa H Shoukry; Rémi Cheynier
Journal:  PLoS One       Date:  2012-04-16       Impact factor: 3.240

5.  Gamma-Delta T-Cell Phenotype and Function in DAA-Treated HIV-HCV Co-Infected and HCV-Mono-Infected Subjects.

Authors:  Valeria Bono; Camilla Tincati; Lorena Van Den Bogaart; Elvira Stefania Cannizzo; Roberta Rovito; Matteo Augello; Anna De Bona; Antonella D'Arminio Monforte; Laura Milazzo; Giulia Marchetti
Journal:  Viruses       Date:  2022-07-22       Impact factor: 5.818

Review 6.  Immune activation and collateral damage in AIDS pathogenesis.

Authors:  Frank Miedema; Mette D Hazenberg; Kiki Tesselaar; Debbie van Baarle; Rob J de Boer; José A M Borghans
Journal:  Front Immunol       Date:  2013-09-26       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.